



# INTERNATIONAL JOURNAL OF PHARMA PROFESSIONAL'S RESEARCH



## Coronary cardiovascular Disease and the Treatment of Atherosclerosis A REVIEW

Mr. Rakesh Bharatia<sup>1\*</sup>, Mr. Shailendra kumar<sup>2</sup>, Mr. Abhishek Jaiswal<sup>3</sup>, Mr. Hariom Jaiswal<sup>4</sup>

ITM COLLEGE OF PHARMACY GIDA GORAKHPUR-273209

**Keywords:** Coronary,  
cardiovascular Atherosclerosis,  
Immunotherapeutics, anti  
inflammatory

### Corresponding Author-

Mr. Rakesh Bharatia

Associate professor

ITM College of Pharmacy

Gida Gorakhpur-273209

Email:

[rakeshpharma786@gmail.co](mailto:rakeshpharma786@gmail.com)

[m](mailto:rakeshpharma786@gmail.com)

Mob no 8707839094

### ABSTRACT:

Coronary cardiovascular disease could be a disorder of the center sometimes cause by a condition known as induration of the arteries. induration of the arteries is one among the main and most frequent causes of Heart arrest. illness|arteriosclerosis|arterial sclerosis|hardening of the arteries|induration of the arteries|coronary-artery disease} is that the disease that affects the massive arteries and it's the condition during which development of plaque happens within these arteries. This causes the narrowing of arteries. Plaque is created of fatty substances, cholesterol, cellular waste product, metallic element and protein (a natural process material within the blood). medicine studies have exhibited many vital risk factors related to induration of the arteries. induration of the arteries} plaque among the coronary arteries is chargeable for arteria coronaria disease, heart muscle misdemeanour and Acute coronary syndromes. Induration of the arteries will cause serious issues, together with heart failure, stroke, or maybe death. This study in the main discusses the mechanism of development of induration of the arteries within the arteries, their risk issue and also the recent advancements to treat the induration of the arteries

### Introduction:

Atherosclerosis is that the illness of arteries. The term arterial sclerosis indicates the formation of fibrofatty lesions within the membrane lining of the arteries like the coronary arteries, the arteria and also

the massive arteries that provide the brain. Arteries are the blood vessels that carry oxygen-rich blood to your heart and different elements of your body. it's the fundamental reason for all deaths within the western world [1-7]. the

danger issue is permanent in aged people, men and case history of premature coronary heart condition. Men are at bigger risk than are biological time ladies, attributable to the protecting effects of natural oestrogens. The presence of lipidemia is that the major risk issue for arterial sclerosis [8-14]. In patients with cardiovascular disease, High vital sign may be a major risk issue for arterial sclerosis that creates a lot of mechanical stress on the vessel epithelial tissue. Chronic uropathy will increase your risk. The causes of arterial sclerosis haven't been determined with certainty. Arterial sclerosis is that the leading reason for unwellness and death in USA and lots of of the developing countries [15-18]. Open access journals give a lot of visibility and accessibility to the readers in gaining the specified info. It provides free and unrestricted access of information via net, that accelerates the scientific discovery. Open access explores the bookish business enterprise, unfold data and permit the data to be engineered upon. Peer reviewed journals publish top quality articles once it's been subjected to multiple critiques by scientists or students in this explicit field [19-22]. The societies are in the main meant for sweetening of Science and technology. we are able to approach several of the scientists and professionals through societies. the most aim is to expand its services and support to scientists and thereby creating folks to know and gain data of various rising innovative technologies. so as to make awareness of arterial sclerosis associated coronary heart condition among the folks, cluster of execs, scientist, physicians and consultants unite to make a society or a corporation. the key societies like European Society of medicine is another international society that in the main targeted in rising advancements in treatment, care and identification and promoted education with reference to hindrance and treatment of upset [23-29]. National Heart Forum of UK is a corporation that in the main aimed in conducting mission that in the main concerned in reducing the risks of coronary heart condition. It additionally promotes researches within the field of vessel diseases. United Heart Foundation of USA promotes the education and activities with reference to the hindrance and treatment of upset through the event of vessel health data and apply [29-34]. Nigerian viscus Society of African nation is related to Omics thereby endorsing the scientific events conducted within the field of medicine. Mongolian, society, for medicine has earned to create a

vision for the event of identification and treatment strategies for the treatment of children's heart condition [35-44]. It additionally trained several medicine cardiologists. The viscus Society of Australia and New Zealand is concerned in promoting the recent advances within the identification and treatment of vessel diseases. These societies in the main worked along to cut back the danger of heart disorders. The society enabled in transfer awareness of heart disorders and helped in understanding the hindrance and treatment of vessel disorders [45-52]. Atherosclerosis: Open Access is that the Journal that provides data and knowledge on totally different aspects of arterial sclerosis and, Coronary arterial sclerosis severity, excretory, organ arterial sclerosis, arteria pathology, Cerebral arterial sclerosis, body part aortal arterial sclerosis and intracranial arterial sclerosis [53-58]. Journal of Clinical & Experimental medicine is Associate in Nursing open access, Journal that explores, the ideas associated, with semilunar, valve Replacement, ontogenesis, heart condition management, X-ray photography and viscus Catheterization. The annual conferences - arterial sclerosis and Clinical medicine that is control throughout July-2016 at USA explored the analysis work on arterial sclerosis that is one the key cause for cardiopathy. This conference in the main targeted on artery arterial sclerosis, arterial sclerosis medical specialty, cardiovascular disease, arterial sclerosis aneurism and the way the plaque hardens and narrows, the, arteries [58-65]. International Journal of vessel analysis aims to publish the reliable supply of knowledge on current analysis and discoveries and in the main focuses on all topics of medicine and vessel medication. Journal of vessel Diseases is peer reviewed journal offers a stress to cavity heart condition, Acute infarction, noninheritable heart condition, control heart diseases, cardiac arrhythmia, Valve Replacement, cardiopathy, Stroke and every one sorts of vessel disorders etc. [65-74]. vessel Pathology: Open Access a world peer-reviewed bookish journal, that revealed the papers across the planet on artery illness as a Special edition in its Volume four [74-79]. Cardiovascular Pharmacology: Open Access Journal studies improve the data and supply last analysis ways for the event of latest medical specialty. International Journal

of vessel analysis may be a leading supplier of knowledge on vessel diseases and novel strategies of treatment followed [79-66]. The on top of mentioned Open access journals on medicine are the peer-reviewed journals that maintain the {standard} and standard of the journal content, reviewer's agreement and various editor's acceptance so as to publish a writing [87-96]. These journals ensure the barrier-free distribution of its content through on-line open access and so helps in rising the citations for authors and attaining smart journal impact factors [97-99].

## MECHANISMS OF THE PROCESS BY WHICH ATHEROSCLEROSIS OCCURS

Early assessment of arterial sclerosis lesions is a vital diagnostic goal so as to decrease the artery disease burden. A writing entitled Clinical Review of Current Techniques of resonance Imaging of arteriosclerosis represented varied vulnerable plaque options and current imaging techniques for police investigation arteriosclerosis and conclude that imaging is best fitted to police investigation early plaque lesions [100-106].

**Endothelial cell injury:** The injury to epithelial tissue vessel layer is that the initial issue development of plaque formation. The doable causes for injury of the epithelial tissue vessel layer are 1) exposure of epithelium to any toxicant substances, which ends within the injury eg: use of tobacco [107-116]. 2) owing to mechanical stress related to cardiovascular disease 3) Immune mechanisms and 4) symptom additionally play a lively role within the pathologic process of the arterial sclerosis lesion.

**Frequency dispersion on the vessel wall - Primary reason of arteriosclerosis by Merab Beraia and Guram Beraia [117-129].**

**Lipoprotein, deposition:** once the epithelium is disabled or noncontinuous, conjugated, protein molecules will gain entry wherever they're then changed by reaction (via free radicals or oxidizing enzymes) or glycation (diabetics) [130-136]. This changed conjugated protein (modified LDL) is inflammatory and ready to be eaten by macrophages making "foam cells" inflicting a "fatty streak" within the blood vessel wall. A writing entitled "Atherosclerosis Associate in Nursing Rheumatic Diseases" mentioned the role of inflammation within the pathophysiology of arteriosclerosis and has given higher data in understanding of arteriosclerosis as an disease [137-146]. clacus Recent advancements within the treatment of arteriosclerosis

Jan Fedacko of European nation is Associate in Nursing professional within the field of bar and treatment, of the arteriosclerosis diseases.

### A. Common approaches:

**1. Usage of HDL:** to spice up the cholesterol role that acts as ally against cardiopathy. One trial drug eg. Torcetrapib – this can be high-density lipoprotein raising path drug [147-150]. This raised considerations which will be it's not the proper quite high-density lipoprotein. All varieties, of high-density, lipoprotein aren't smart.

### 2. anti inflammatory:

Inflammation plays a serious role for the formation of plaque and sequent plaque rupture, that finally results, in heart, failure [151,160]. Statins has medicament effects that facilitate in preventing plaque rupture and even have property of lowering LDL cholesterol [161-173]. Still we want to seek out an honest medical care or the drug that specifically stop the inflammation or rupture of the artery wall, by assaultive root causes. The lowering of lipoprotein sterol by statin therapy has been mentioned within the article- Lipid-lowering methods and reduction of coronary cardiopathy risk in medical aid written by Ersin Ekpinar, of USA [174-183].

### B. Immunotherapeutics approaches:

**1. macromolecule primarily based vaccines:** This therapeutic approach in the main deals with inhibition, of arterial sclerosis lesion, formation [183-192].

**2. supported Epitopes of modify low-density lipoprotein:** the various epitopes of modify LDL is an efficient tool for the modulation of the response to OxLDL. These epitopes of modify low-density lipoprotein induce atherogenic immune responses [193-215]. Most of studies ended that this, therapeutic, approach, reduces, the arteriosclerosis.

**3. Heart, Shock, proteins:** pathology to, heat-shock, proteins, is one component in arteriosclerosis elicited immune, responses. recurrent tissue, layer administration of true bacteria HSP60/65, each orally and nasally, smothered arterial sclerosis lesion formation in LDL-receptor-deficient mice [197-200].

## CONCLUSION

Atherosclerosis is taken into account as

a cardiopathy, though it will have an effect on any a part

of the body. we've mentioned the mechanism, of the method by that arteriosclerosis happens, however still wants a progress within the discover of the precise and actual mechanism of action. The approaches like lowering low-density lipoprotein by interference the impact of PCSK9, and a technique of treating arteriosclerosis showed promising effects in reducing the residual risk that even remains when current medical care. In recent days, the scientists and researchers copied new approaches by introducing therapeutic targets for the immunoregulation of arteriosclerosis. to seek out right balance between efficaciousness and safety can in all probability need a a lot of variety of trials to assess a spread of drug mechanisms to treat arteriosclerosis.\

## REFERENCES

1. Esther SerranoPertierra, et al. Lysophosphatidylcholine Induces Vascular Smooth Muscle Cell Membrane Vesiculation: Potential Role in Atherosclerosis through Caveolin-1 Regulation. *J Proteomics Bioinform.* 2014;7:332-339.
2. Kunal Mahajan. Interleukin-18 and Atherosclerosis: Mediator or Biomarker. *J Clin Exp Cardiol.* 2014;5:352.
3. Marcello Camici, et al. Obesity and Increased Risk for Atherosclerosis and Cancer. *Intern Med.* 2014;4:154.
4. Kunal Mahajan. Microparticles in Atherosclerosis: Biomarkers of Disease. *J Clin Exp Cardiol.* 2015; 5:356.
5. Maya Mattar, et al. Atherosclerosis and Rheumatic Diseases. *Rheumatology (Sunnyvale).* 2015;1000147.
6. Paola C Roldan. et al. Aortic Atherosclerosis in Systemic Lupus Erythematosus. *Rheumatology.* 2014;S5-006.
7. Camici M, et al. Obesity and Increased Risk for Atherosclerosis and Cancer. *Intern Med.* 2014;4: 154.
8. Hadi NR, et al. Effect of Vildagliptin on Atherosclerosis Progression in High Cholesterol–Fed Male Rabbits. *J Clin Exp Cardiol.* 2013;4:249.
9. Bolli G, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab.* 2008;10: 82-90
10. Jahaira Lopez Pastrana, et al. Regulatory T Cells and Atherosclerosis. *J Clin Exp Cardiol.* 2012;S12-002.
11. Suowen Xu. Rock the Rock of Atherosclerosis. *J Vasc Med Surg.* 2013;1:e101.
12. Chiharu Kishimoto and Zuyi Yuan. The Role of Fcγ Receptors in Myocardial Diseases and Atherosclerosis. *J Clin Cell Immunol.* 2012;S10: 004.
13. Najah R Hadi, et al. Monteleucast and Zileuton Retard the Progression of Atherosclerosis via Down Regulation of the Inflammatory and Oxidative Pathways. *J Clin Exp Cardiol* 2013;4:250.
14. Manchanda SC, et al. Reversal of Early Atherosclerosis in Metabolic Syndrome by Yoga – A Randomized Controlled Trial. *J Yoga Phys Ther* 2013;3:132.
15. Roever L, et al. Insulin Resistance, Type 2 Diabetes and Atherosclerosis. *J Diabetes Metab.* 2014;5:464.
16. Jacek Jawien. Mouse Experimental Models of Atherosclerosis in Pharmacology. *J Clin Exp Cardiol.* 2011;S1-001.
17. Maya Mattar, et al. Atherosclerosis and Rheumatic Diseases. *Rheumatology (Sunnyvale)* 2015;1000147.
18. Wagner Ramos Borges, Andre Mauricio Souza Fernandes, Andre Rodrigues Duraes, Roque Aras Junior and Joao Lima, Subclinical Atherosclerosis in Non-dialysis Chronic Renal Patients. *J Cardiovasc Dis Diagn* 2015;3: 189
19. Roever L, et al. Insulin Resistance, Type 2 Diabetes and Atherosclerosis. *J Diabetes Metab* 2014;5:464
20. Kunal Mahajan. Interleukin-18 and Atherosclerosis: Mediator or Biomarker. *J Clin Exp Cardiol* 2014;5:352
21. Kunal Mahajan. Microparticles in Atherosclerosis: Biomarkers of Disease. *J Clin Exp Cardiol* 2015;5: 356.
22. Turiel M, et al. Strategies for Early Identification of Atherosclerosis in Systemic Autoimmune Disease. *J Cardiovasc Dis Diagn.* 2014;2: 167
23. Patel A. Does the Role of Angiogenesis Play a Role in Atherosclerosis and Plaque Instability? *Anat Physiol* 2014;4: 147.
24. Marcello Camici, et al. Obesity and Increased Risk for Atherosclerosis and Cancer. *Intern Med* 2014, 4: 154.
25. Paul BhamraAriza. The Assessment and Management of Coronary Artery Disease in Patients with HIV. *J AIDS Clin Res.* 2014;5: 283

26. Ames PRJ, et al. Atherosclerosis in Primary Antiphospholipid Syndrome: Summary of Clinical and Pathogenic Evidence. *J Clin Exp Cardiol.* 2014;5:293
27. Rogil J and Torres DA. AMD and Atherosclerosis: Physiopathogenic Similarities and Possible Therapeutics. *J Clin Exp Ophthalmol.* 2012;3: e111
28. Jahaira Lopez, et al. Regulatory T Cells and Atherosclerosis. *J Clin Exp Cardiol.* 2012;S12-002
29. Alessandro Mauriello and Giuseppe Sangiorgi. Inflammation and Atherosclerosis: Evolving Concepts Leading the Development of New Therapies. *J Metabol Syndro.* 2012;1:e106
30. Chiharu Kishimoto and Zuyi Yuan. The Role of Fcγ Receptors in Myocardial Diseases and Atherosclerosis. *J Clin Cell Immunol.* 2012;S10: 004.
31. Paula Blair and Pasquale Maffia. Revisited Role of B Cells in Atherosclerosis. *Pharm Anal Acta.* 2012;3:174.
32. Kim YH, et.al. Biased Agonism of G Protein-Coupled Receptors: A Potential Therapeutic Strategy of Cardiovascular Diseases. *Cardiovasc Pharm Open Access.* 2016;5:192.
33. Alam MA. Methylenetetrahydrofolate Reductase Gene Polymorphisms and Cardiovascular Diseases. *Cell Dev Biol.* 2016;5:172.
34. Altura BM, et.al. Genotoxic Effects of Magnesium Deficiency in the Cardiovascular System and their Relationships to Cardiovascular Diseases and Atherogenesis. *J Cardiovasc Dis Diagn.* 2016;S1:008.
35. Afroz R, et.al. Honey-derived Flavonoids: Natural Products for the Prevention of Atherosclerosis and Cardiovascular Diseases. *Clin Exp Pharmacol.* 2016;6:208.
36. Maksimovich IV. Transcatheter Cerebral Revascularization in the Treatment of Atherosclerotic Lesions of the Brain. *Brain Disord Ther.* 2016;5:209.
37. Mohri T, et al. Factors Affecting Recurrence of T1 and T2 Tongue Cancer Undergoing Intraoral Resection. *Otolaryngology.* 2016;6:224.
38. Berezin. Are Endothelial Cell-Derived Microparticles Predictive Biomarkers in Cardiovascular Diseases? *Atheroscler open access.* 2016;1:e101.
39. Zafar R. A New Insight into Pathogenesis of Cardiovascular Diseases: Stress Induced Lipid Mediated, Vascular Diseases. *J Cardiovasc Dis Diagn.* 2015;3:206.
40. Askari R, et.al. Quinine Syncope Diagnosed by Life Vest. *Clin Exp Pharmacol.* 2015;5:172.
41. Abd-Elbaky AE, et.al. Associations of Serum Omentin and Apelin Concentrations with Obesity, Diabetes Mellitus Type 2 and Cardiovascular Diseases in Egyptian Population. *Endocrinol Metab Synd.* 2015;4:171.
42. Zafar R. An Insight into Pathogenesis of Cardiovascular Diseases. *J Cardiovasc Dis Diagn.* 2015;3:197.
43. Refaat B, et.al. Islamic Wet Cupping and Risk Factors of Cardiovascular Diseases: Effects on Blood Pressure, Metabolic Profile and Serum Electrolytes in Healthy Young Adult Men. *Altern Integr Med.* 2014;3:151.
44. Vasco VRL, et al. Hunting the Risk NPY and ACE Polymorphisms as Predictors of Cardiovascular Diseases: Case Report and Review of the Literature. *Intern Med.* 2014;S11:004.
45. Greco OT, et al. Cardiomyopathy and Cell Therapy: Ejection Fraction Improvement and Cardiac Muscle Mass Increasing, after a Year of Bone Marrow Stem Cells Transplantation, by Magnetic Resonance Image. *J Stem Cell Res Ther.* 2013;S6:008.
46. Charkha N, et.al. Estimating Risk of Mortality from Cardiovascular Diseases using Negative Binomial Regression. *Epidemiol.* 2013;3:127.
47. Alawieh A, et.al. Metabolomics in Cardiovascular Diseases: Biomarkers Quest. *J Data Mining Genomics Proteomics.* 2013;S2:e001.
48. Hanefeld M, et.al. The Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical Treatment. *J Metabolic Synd.* 2014;3:160.
49. Dave MB. Pioglitazone: A Better Choice of Drug in the Pre-diabetic Patients with High Risk of Cardiovascular Diseases. *J Diabetes Metab.* 2014;5:447.
50. Skultetyova D, et al. The Impact of Blood Pressure on Carotid Artery Stiffness and Wave Intensity in Patients with Resistant Hypertension after Renal Sympathetic Denervation. *J Hypertens.* 2014;3:157.
51. Ritu M and Manika M. Blood Homocystiene and Lipoprotein (A) Levels, Stress and Faulty Diet as Major Risk Factors for Early Cardiovascular Diseases in Indians. *J Cardiovasc Dis Diagn.* 2014;2:163.
52. Han J, et.al. Stem Cell Therapy in Cardiovascular Diseases: The Reparative Mechanisms of

Mesenchymal Stem Cells for Myocardial Infarction Treatment. *J Cell Sci Ther.* 2014;5: 167.

55. Patel NKJ, et al. Metabolic Syndrome and its Impact on Cardiovascular Diseases. *J Metabolic Syndr.* 2014;3:142.

56. Soejima H, et al. The Changes of Biomarkers by Telmisartan and their Significance in Cardiovascular Outcomes: Design of a Trial of Telmisartan Prevention of Cardiovascular Diseases (ATTEMPT-CVD). *J Clin Trials.* 2014;4:162.

57. White HS, et.al. Mechanisms of Action of Human Aldehyde Dehydrogenase Bright Cells in Therapy of Cardiovascular Diseases: Expression Analysis of Angiogenic Factors and Aldehyde Dehydrogenase Isozymes. *J Stem Cell Res Ther.* 2011;S1:001.

58. Lavoie M, et.al. Blood Glutathione Peroxidase Activity in Relation with the Risk of Cardiovascular Diseases in Obese Women. *J Diabetes Metab.* 2011;2:136.

59. Maramao F, et.al. Radiotherapy-Chemotherapy Related Heart Diseases in Surgical Setting. *J Clin Exp Cardiol.* 2016;7:444.

60. Zhou Y, et.al. Clinical Trials Using Cell-based Therapy in Ischemic Heart Diseases - A Decade's Efforts. *J Vasc Med Surg.* 2015;3:174.

61. Maduagu ATL, et.al. Prevalence of Coronary Heart Diseases Risk Factors in Adults Population Living in Nigeria's Largest Urban City. *J Nutr Disorders Ther.* 2015;5:153.

62. Cen J, et.al. Study on the Features of Coronary Artery Atheromatous Plaque for Patients with Impaired

63. Glucose Tolerance when Applying Intravascular Ultrasound. *Cardiovasc Pharm Open Access.* 2016;5:177.

64. Munesh T, et.al. Acute Cardiorespiratory Decompensation in a Child with Nephrotic syndrome with Bronchial Asthma: Is it Exaggeration of Bronchial Asthma? *Clin Pediatr.* 2016;1:104.

65. Chelo D, et.al. Challenges of Surgical Management of Childhood Cardiac Diseases in Sub-Saharan Africa, Experience of a Pediatric Cardiology Unit in Yaounde, Cameroon. *Int Ped Res.* 2016;1:103.

66. Ibraimov AI. Chromosomal Q-Heterochromatin Polymorphism in Patients with Alimentary Obesity. *Biol Med.* 2016;8:275.

67. Mustapha C. Giant Submandibular Duct Calculus: A Case Report. *Surgery Curr Res.* 2015;6:253.

68. Refaat B, et.al. Islamic Wet Cupping and Risk Factors of Cardiovascular Diseases: Effects on Blood Pressure, Metabolic Profile and Serum Electrolytes in Healthy Young Adult Men. *Altern Integr Med.* 2014;3:151.

69. Vasco VRL, et al. Hunting the Risk NPY and ACE Polymorphisms as Predictors of Cardiovascular Diseases: Case Report and Review of the Literature. *Intern Med.* 2014;S11:004.

70. Greco OT, et al. Cardiomyopathy and Cell Therapy: Ejection Fraction Improvement and Cardiac Muscle Mass Increasing, after a Year of Bone Marrow Stem Cells Transplantation, by Magnetic Resonance Image. *J Stem Cell Res Ther.* 2013;S6:008.

71. Charkha N, et.al. Estimating Risk of Mortality from Cardiovascular Diseases using Negative Binomial Regression. *Epidemiol.* 2013;3:127.

72. Alawieh A, et.al. Metabolomics in Cardiovascular Diseases: Biomarkers Quest. *J Data Mining Genomics Proteomics.* 2013;S2:e001.

73. Kpadonou TG, et al. Preliminary Results of a Cardiac Rehabilitation Program in Patients with Compensated Heart Diseases in Sub-Saharan Africa (Benin): A Pilot Study. *Int J Phys Med Rehabil.* 2013;1:160.

74. Sauza-Sosa JC. Torsades De Pointes Induced by Levofloxacin in an Unknown Long QT Syndrome Cardiovasc Pharm Open Access. 2016;5:191.

75. López MES, et al. Association of the Presence of the IS6110 Gene and the Polymorphisms of the Receptor of the Bactericide P2X7 (A1513C and -762 C/T) in Mexican Patients with Takayasu's Arteritis and Tuberculosis. Is the Vasculitis A Manifestation of Extrapulmonary Tuberculosis?. *J Vasc.* 2016;2:109.

76. Yajun Gu, et.al. Early Subclinical Biomarkers in Onco-Cardiology to Prevent Cardiac Death. *Cardiovasc Pharm Open Access.* 2016;5:183.

77. Lamin V, et al. Endothelial Denudation of Isolated Human Internal Mammary Artery Segments. *Cardiovasc Pharm Open Access.* 2016;5:180.

78. Alawieh A, et.al. Metabolomics in Cardiovascular Diseases: Biomarkers Quest. *J Data Mining Genomics Proteomics.* 2013;S2:e001.

79. Elio G, et al. LOX-1 and its Implications on Cardiovascular Diseases a Possible New Perspective Target on Atherosclerosis. *J Clin Exp Cardiol.* 2013;4:232.

80. Izumi Y. Therapeutic Potential of Microvesicles in Cardiovascular Diseases. *J Genet Syndr Gene Ther.* 2012;3:e107.
81. Nishant T, et.al. Pharmacogenomics- Personalized Treatment of Cancer, Diabetes and Cardiovascular Diseases. *J Pharmacogenomics Pharmacoproteomics.* 2011;2:107.
82. Srilatha B. High Risk Factors of Cardiovascular Diseases in Type 2 Diabetes. *J Diabetes Metab.* 2011;2:164.
83. Loh LC, et.al. Undiagnosed COPD in Patients with Established Cardiovascular Diseases: Prevalence, Symptoms Profiling and Functional Status. *J Pulmonar Respirat Med.* 2011;1:107.
85. Aronow WS. 2015 American Heart Association/American College of Cardiology/American Society of
86. Hypertension Guidelines on Treatment of Hypertension in Patients with Coronary Artery Disease. *J Hypertens.* 2015;4:e113.
87. Sinan UY. The Cardiac Related Thrombocytopenia. *J Hematol Thrombo Dis.* 2015;3:216.
88. Hassebo MFH, et.al. Correlation between P Wave Dispersion, QRS Duration and QT Dispersion in Hospital
89. Events in Cases of Acute Coronary Syndrome. *J en Pract.* 2015;3:196.
90. Kruk M, et al. Impact of Selection Criteria on Outcomes of Antithrombotic Trials in Acute Coronary Syndromes. *J Clin Trials.* 2015;5:220.
91. Madan T, et.al. Endovascular Intervention in Chronically Occluded Inferior Vena Cava with Modified Sharp Recanalization Technique. *J Clin Case Rep.* 2015;5:512.
92. Mahmood H, et.al. Relation of Cholesterol Level to Dietary Fat Intake in Patients of Ischemic Heart Disease. *Cardiol Pharmacol.* 2015;4:141.
93. 82. Bolognesi M. The Importance of the Electrocardiogram (Ecg) in the Setting of Sports Pre-Participation Screening. *J Clin Case Rep.* 2014;4:e136.
94. Sadiq N. Transhepatic Approach for Device Closure of Secundum Atrial Septal Defect in Patient with Interrupted Inferior Vena Cava. *Cardiol Pharmacol.* 2014;3:120.
95. 84. Shukla AN, et.al. The Prevalence of Hypertension: Role of Hereditary in Young and Obesity in all. *J Hypertens.* 2014;3:156.
96. Bolognesi M and Prutkin JM. Sudden Cardiac Death in a Female Triathlete: Complexities of Risk Stratification. *Intern Med.* 2014;4:161.
97. Lucas A, et.al. Women in Cardiology: The X Factor and the Heart of Medicine. *J Clin Exp Cardiol.* 2014;5:e134.
98. Gupta PN, et.al. Endomyocardial Fibrosis and the Prothrombotic State: From Hypercoagulability to Protien C Deficiency. *J Blood Disord Transfus.* 2013;5:187.
99. Kshemada K, et.al. Forensic Sciences and Growth of Cardiology. *J Forensic Res.* 2013;5:e115.
100. Brieke A, et.al. Management of Calcineurin Inhibitors-Related Chronic Kidney Disease in Cardiac Transplantation. *J Cardiovasc Dis Diagn.* 2013;1:117.
101. Cambe J, et al. Clinical Review of Current Techniques of Magnetic Resonance Imaging of Atherosclerosis. *J Vasc Med Surg.* 2015;3:227.
102. Ninkovic VM, et al. Predictors of In-Hospital Mortality in Patients with Acute Inferior Infarction of the Left Ventricle Accompanied by Right Ventricular Infarction when Treated with Percutaneous Coronary Intervention. *J Clin Exp Cardiol.* 2013;4:253.
103. Buttrick P. TAVR: Is The Glass Half Empty or Half Full? A Non-Interventional Cardiologist's View of a New Technology. *J Cardiovasc Dis Diagn.* 2013;1:e102.
104. Olimulder MAGM, et al. Relationship between Framingham Risk Score and Left Ventricular Remodeling after Successful Primary Percutaneous Coronary Intervention in Patients with First Myocardial Infarction and Single-Vessel Disease. *J Clin Exp Cardiol.* 2013;4:241.
105. Roberto B. Criptogenetic Cerebral Ischemia and Spongious Atrial Septum. A New Culprit? *J Clin Case Rep.* 2012;2:233.
106. Philipp S, et al. Induction of Hypoxia Inducible Factor Rather than Modulation of Collagen Metabolism Improves Cardiac Function and Reduces Left Ventricular Hypertrophy after Aortocaval Shunt in Rats. *J Clin Exp Cardiol.* 2013;4:227.
107. de Gregorio C. Preparticipation Screening of Young Athletes: Why Still Open Questions on Performing an Electrocardiogram? *J Clin Exp Cardiol.* 2013;3:e117.

108. Philipp S, et al. The Appraisal-Trial: Evaluating RESTEN-MPTM in Patients with Bare Metal Stent De Novo Native Coronary Artery Lesions. *J Clin Exp Cardiol.* 2012;3:218.
109. Kpadonou TG, et al. Preliminary Results of a Cardiac Rehabilitation Program in Patients with Compensated Heart Diseases in Sub-Saharan Africa (Benin): A Pilot Study. *Int J Phys Med Rehabil.* 2013;1:160.
110. Sauza-Sosa JC. Torsades De Pointes Induced by Levofloxacin in an Unknown Long QT Syndrome. *Cardiovasc Pharm Open Access.* 2016;5:191.
111. López MES, et al. Association of the Presence of the IS6110 Gene and the Polymorphisms of the Receptor of the Bactericide P2X7 (A1513C and -762 C/T) in Mexican Patients with Takayasu's Arteritis and Tuberculosis. Is the Vasculitis A Manifestation of Extrapulmonary Tuberculosis?. *J Vasc.* 2016;2:109.
112. Yajun Gu, et.al. Early Subclinical Biomarkers in Onco-Cardiology to Prevent Cardiac Death. *Cardiovasc Pharm Open Access.* 2016;5:183.
113. Lamin V, et al. Endothelial Denudation of Isolated Human Internal Mammary Artery Segments. *Cardiovasc Pharm Open Access.* 2016;5:180.
114. Demir M and Demir C. Mean Platelet Volume is Increased in Patients with Atrial Septal Aneurysm. *J Clin Exp Cardiol.* 2012;3:200.
115. Tarcin O, et.al. Glycemic Profiles and Their Diagnostic Value among Inpatients in a Cardiology Clinic. *Endocrinol Metab Synd.* 2012;S5:005.
116. Elio G, et al. LOX-1 and its Implications on Cardiovascular Diseases a Possible New Perspective
117. Target on Atherosclerosis. *J Clin Exp Cardiol.* 2013;4:232.
118. Ali SA. Use of Smokeless Tobacco in Medical Students and Hypertension. *Occup Med Health Aff.* 2016;4:240.
119. Stoicescu M. The Risk of Sudden Decrease of Severe Arterial Hypertension . *J Clin Exp Cardiol.* 2016;7:460.
120. Chauhan R, et al. Hypertension and the Aged. *J Gerontol Geriatr Res.* 2016;S5:002.
121. Pagano D, et al. Portal Hypertension Model in Pigs. *J Clin Exp Transplant.* 2016;1:e101.
122. Aberha M, et al. Prevalence and Factors Associated with Anxiety among Patients with Hypertension on Follow Up at Menelik- II Referral Hospital, Addis Ababa Ethiopia. *J Psychiatry.* 2016;19:378.
123. Trailokya A. Will Azilsartan - An Eight ARB Bring Paradigm Shift in Hypertension Management Practices in India? *Cardiovasc Pharm Open Access.* 2016;5:189.
124. Li M, et al. To Live Long, Eat Less Salt: Salt Intake Reduction Promotion and Hypertension Control in China. *Health Care: Current Reviews.* 2016;4:169.
125. Soltani HM, et al. The Effect of Fasting During Ramadan on Blood Pressure in Patients with Controlled and Mild Hypertension. *J Hypertens.* 2016;5:227.
126. Berezin AE. Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression? *Clin Med Biochemistry Open Access.* 2016;2:114.
127. Manolis A. Erectile Function in Cardiovascular Disease and Hypertension: the Role of Nebivolol . *J Hypertens.* 2016;5:226.
128. Lv Y, et al. Non-Hypersplenism Causes of Peripheral Cytopenias in Patients with Cirrhotic Portal Hypertension: A Review. *J Hypertens.* 2016;5:223.
129. Li X, et al. Angiotensinogen M235T,  $\beta$ 2 Adrenergic Receptor Arg16Gly and Aldosterone Synthase C-344T Gene Polymorphisms and Essential Hypertension among Han Population Living at High Altitude in China. *J Hypertens.* 2016;5:222.
130. Abdel-hamid ER, et al. Association of Angiotensin Converting Enzyme Gene Polymorphism and Possible High Risk Factors with Essential Arterial Hypertension in Egyptian Patients. *Mol Biol.* 2016;5:165.
131. EL-Adawy NM, et al. Fibroblast Growth Factor-23: A Possible Cause of Pulmonary Hypertension and Left Ventricle Hypertrophy in Hemodialysis Patients. *J Clin Exp Cardiol.* 2016;7:449.
132. Feyh A, Bracero L, et al. Role of Dietary Components in Modulating Hypertension. *J Clin Exp Cardiol.* 2016;7:433.
133. Guney F, et al. Intracranial Hypertension in Behcet Disease: A Case Report. *J Clin Case Rep.* 2016;6:748.
134. Bogari DF, et al. The Prevalence of Hypertension in Endodontic Clinics: A Pilot Study. *Dentistry.* 2016;6:370.



135. Silva RP, et al. Who is the Patient with Suspected White Coat Hypertension? *J Clin Exp Cardiol.* 2016;7:428.
136. Aissa S, et al., Prognosis Evaluation of Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension. *J Pulm Respir Med.* 2016;6:328.
137. Li H. Hypertension Management in Primary Care in China: Still a Long Way to Proceed. *J Gen Practice.* 2016;4:238.
138. Mattar Met, et al. Atherosclerosis and Rheumatic Diseases. *Rheumatology (Sunnyvale)* 2015;5:147.
139. Tsabang N, et al. Comparative Study of Epidemiological and Anthropological Aspects of Diabetes and Hypertension in Cameroon. *Forest Res.* 2016;5:165.
140. Dash SK, Kulkarni V, Sahoo RK, Macherla G, Ravikiran M Idiopathic Pulmonary Hypertension Induced Thrombocytopenia - A Case Report. *J Pulm Respir Med* 6:322.
141. Huckabay L, et al. Hypertension in a Low-income and Homeless Community Sample. *J Community Med Health.* 2016;6:399.
142. Gonzalez-Aguirre AJ, et al. Transjugular Liver Biopsy in a Multiple Myeloma Patient with Hepatomegaly, Portal Hypertension and “Miliary” Liver Lesions: A Case Report. *J Gastrointest Dig Syst.* 2016;6:390.
143. Kamal I, et al. Kidneys: The Victim Of Hypertension: Review. *J Nephrol Ther.* 2016;6:231.
144. Mussa BM, et al. Prevalence of Hypertension and Obesity among Emirati Patients with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:638.
145. Viggiano A, et al. Anti-Hypertensive Treatments and Hypertension- Associated Hypoalgesia Evaluated by Auto-Algometry. *J Anesth Clin Res.* 2015;6:589.
146. Bos AJG, et al. Comparing the Prevalence and Drug Treatment Rates of Diabetes, Hypertension and Dyslipidemia between Japan and Brazil, using 2013 National Health Surveys. *J Clin Diabetes Pract.* 2015;1:103.
147. Yunfu Lv, Han XY, Gong X, Gu W, He C, et al. Analysis of Peripheral Blood Cells Due to Adults Posthepatic Cirrhotic Portal Hypertension and Their Postoperative Prognosis. *J Hypertens (Los Angel)* 4:210.
148. Al-Hamdan NA. Isolated Systolic Hypertension among Adults in Saudi Arabia: Prevalence, Risk Factors, Predictors and Treatment - Results of a National Survey. *Epidemiology (sunnyvale).* 2015;5:206.
149. Lerman MJ, et al. Post Kidney Transplant Refractory Hypertension and Bilateral Native Nephrectomy. *J Kidney.* 2015;1:107.
150. Safdar Z, et al. Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension. *J Pulm Respir Med.* 2015;5:295.
151. Ashoor I . Pediatric Hypertension: A Primer for the Busy Primary Care Provider. *J Nephrol Ther* 5:218.
152. Mutlu E, et al. Comparative Effectiveness of Novokinin, Perindopril and Losartan on Blood Pressure, Adma, Nadph Oxidase and Rho Kinase at Renal Tissue in L-Name and Salt Induced Hypertension. *Clin Exp Pharmacol.* 2015;5:197.
153. Herbert S, and Tulloh RMR. Treatment of Pulmonary Hypertension in Down’s Syndrome. *J Genet Syndr Gene Ther.* 2015;6:273.
154. Roever L and Borges ASR. Pulmonary Hypertension and Exercise Training: Evidence Based Studies. *Lung Dis Treat.* 2015;1:e103.
155. Al-Saloos H and Saeed S. Rare Case of Bilateral Superior Vena Cava, Persistent Left Superior Vena Cava Draining to Coronary Sinus, Absent Bridging Vein, Interrupted Inferior Vena Cava with Azygos Vein Continuation to Right Superior Vena Cava, Situs Inversus and Pulmonary Hypertension in a Neonate: A Case Report. *Pediat Therapeut.* 2015;5:i110.
156. Strażyńska A, et al. The Relationship between Serum Apelin Concentration and Selected Anthropometric Parameters, Serum Lipids and Carotid Intima-Media Thickness in Young Subjects with Primary Arterial Hypertension. *J Metabolic Syndr.* 2015;4:185.
157. Plácido R, et al. Predictors of Functional Capacity in Patients with Pulmonary Hypertension. *J Pulm Respir Med.* 2015;5: 290.
158. Rajekar H. Complication of Cirrhosis Portal Hypertension: A Review. *J Liver* 2015;4:188.
159. Roever L. High-Sensitivity C-Reactive Protein, Hypertension and Stroke: Cause and Effect or Simple Association?. *InternMed.* 2015;5:e102.
160. Sun Y, et al. Pulmonary Arterial Hypertension from Hepatic HHT. *InternMed.* 2015;5:109.
161. Aronow WS. 2015 American Heart Association/American College of

Cardiology/American Society of Hypertension Guidelines on Treatment of Hypertension in Patients with Coronary Artery Disease. *J Hypertens.* 2015;4:e113.

162. Jiangyan C, et al. Association among Systolic Blood Pressure Variation, Inflammation and Arterial Rigidity in Essential Hypertension. *J Hypertens.* 2015;4:207.

163. Padda RS, et al. Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?. *J Diabetes Metab.* 2015;6:615.

164. Rovedder PME, et al. Pulmonary Hypertension and Pulmonary Disorders in Cystic Fibrosis. *Cardiovasc Pharm Open Access.* 2015;4:158.

165. Vadapalli S, et al. Variants of PGIS and PPAR $\gamma$  in Idiopathic Pulmonary Arterial Hypertension. *J Clin Med Genomics.* 2015;3:130.

166. Srinivasamurthy BC. Burden and Determinants of Hypertension in Rural Pondicherry, India. *J Clin Med Genomics.* 2015;3:127.

167. Nikitin VA, et al. Concor AM Therapy in Patients with Chronic Obstructive Pulmonary Disease and Concomitant Arterial Hypertension. *Biol Med* 2015;7:246

168. Boos CJ, et al. The Effects of Ascent and Descent on Heart Rate and Rhythm at High Altitude. *J Clin Exp Cardiol.* 2016;7:462.

169. Zaidi SN and Collins SM. Orthostatic Stress Induced Changes in Heart Rate Variability, Pulse Transit Time and QRS Duration. *J Bioengineer & Biomedical Sci.* 2016;6:194.

170. Gonsorcik J, et al. Atrioventricular Nodal Reentrant Tachycardia in Transplanted Heart. *J Clin Exp Cardiol.* 2016;7:458.

171. Zhang J, et al. A Comparison of Haemodynamic Effects and Safety between Domestic Levosimendan versus Dobutamine for Hospitalized Patients with Acute Decompensated Heart Failure. *Cardiovasc Pharm Open Access.* 2016;5:186.

172. Berezin AE. Progenitor Endothelial Cell Dysfunction in Heart Failure: Clinical Implication and Therapeutic Target?. *Transl Med (Sunnyvale).* 2016;6:176.

173. Gabaev DD. How I Reached the Age of 65 with a Congenital Heart Disease and atherosclerosis. *Anat Physiol.* 2016;6:228.

174. Suastika K, et al. Coronary Heart Disease in a Remote Area. *J Clin Exp Cardiol.* 2012;S6:002.

175. Namekata T, et al. Association of Cardio-Ankle Vascular Index with Cardiovascular Disease Risk Factors and Coronary Heart Disease among Japanese Urban Workers and their Families. *J Clinic Experiment Cardiol.* 2012;S1:003.

176. Spencer-Hwang R, et al. Female Renal Transplant Recipients Potentially at Increased Risk of Fatal Coronary Heart Disease Associated with Ambient Air Pollutants. *J Clinic Experiment Cardiol.* 2011;S6:001.

177. Mehta P, et al. Growth and Tolerability of Healthy Term Infants Fed a New Formula Supplemented with DHA from Schizochytrium sp Microalgae. *J Vasc Med Surg.* 2016;4: 267.

178. Berezin AE, et al. Epigenetic Modifications the Development of Different Heart Failure Phenotypes. *J Data Mining Genomics & Proteomics.* 2016; 7:202.

179. Svetikiene M, et al. Successful Treatment of Right Heart Thrombi and Acute Massive Pulmonary Embolism by Repeated Thrombolysis. *J Clin Exp Cardiol.* 2016; 7: 451.

180. Todurov B, et al. Usefulness of Applying Temporary Intracoronary Shunts for Myocardial Revascularization. *Biol Med (Aligarh).* 2016;8: 302.

181. Firoj KM, et al. Myocardial Protective Effect of Exogenous Creatine Phosphate in Children Undergoing Open Heart Surgery. *J Clin Exp Cardiol.* 2016;7: 450.

182. Mbamalu ON, et al. HPLC Determination of Selected Flavonoid Glycosides and their Corresponding Aglycones in *Sutherlandia frutescens* Materials. *Med Aromat Plants.* 2016;5:246.

183. Alkhatib EA, et al. Multi-Regression Prediction of Metal Partition Coefficients under Various Physical/Chemical Conditions “Design of Experiments As, Cr, Cu, Ni and Zn”. *Hydrol Current Res.* 2016;7:241.

184. Sanchez JM, Kurian T, Doshi A, Pieper S Fever Exacerbating Ventricular Fibrillation in Early Repolarization Syndrome. *J Cardiovasc Dis Diagn.* 2016;S1:006.

185. Mumphrey CG, et al. Hypoplastic Left Heart Syndrome in a Patient with Fetal Hydantoin Syndrome. *J Neonatal Biol.* 2016;5:217.

186. Kiuchi MG, et al. Effects of Renal Sympathetic Denervation in Comparison to  $\beta$ -Blocker on Heart Rate Control in Hypertensive Patients with Permanent Atrial Fibrillation. *J Clin Exp Cardiol.* 2016;7:439.

187. Scaldaferrri F, et al. Emerging Mechanisms of Action and Loss of Response to Influximab in Ibd: A Broader Picture. *Biochem Pharmacol.* 2016;5:206.
188. Berezin AE. The Role of Circulating Myeloid-Related Protein Complex Calprotectin in Prediction of Heart Failure with Preserved Ejection Fraction . *J Clin Exp Cardiol.* 2016;7:436.
189. Ilori TO, et al. The Arteriovenous Fistula: An Often Overlooked Precipitant of High Output Heart Failure. *J Clin Case Rep.* 2016;6:751.
190. Watanabe T, et al. Pacemaker Lead Perforation during Right Ventricular Outflow Tract Pacing - Importance of Heart Rotation at Pacemaker Implantation. *J Clin Case Rep.* 2016;6:707.
191. Wang JY, et al. Aortic Dissection Secondary to Maguog Ingestion. *J Vasc Med Surg.* 2016;4:256.
192. Wang JY, et al. Acute Myocardial Infarction Secondary to Aortic Dissection. *J Vasc Med Surg .* 2016;4:255.
193. Ahsan S, et al. A Classic Presentation of Lyme Complete Heart Block. *Trop Med Surg.* 2016;4:207.
194. Algazzar AS, et al. Changes in Left Ventricular Global and Regional Longitudinal Strain during Right Ventricular Pacing. *Arrhythm Open Access.* 2016;1:107.
195. Campbell AB, et al. Ventricular Tachycardia in a Patient with Repaired Tetralogy of Fallot. *J Gen Pract.* 2013;1:120.
196. Schmitz G and Rezaie S. Do Elevated Troponins during Supraventricular Tachycardia (SVT) Predict the Presence of Coronary Artery Disease? *Emergency Med.* 2013;3:e132.
197. Porpino SKP, et al. Developing New Organic Nitrates for Treating Hypertension: A Review. *J Hypertens.* 2016;5:232.
198. Chaowu Y, et al. Diastolic Pulmonary Arterial Pressure as a Prognostic Indicator for Closure of Atrial Septal Defect with Severe Pulmonary Arterial Hypertension . *J Hypertens. .* 2016;5:231.
199. Nole T, et al. Ethnomedical and Ethnopharmacological Study of Plants Used For Potential Treatments of Diabetes and Arterial Hypertension by Indigenous People in Three Phytogeographic Regions of Cameroon. *Diabetes Case Rep.* 2016;1:110.
200. Zha P, et al. An RN/CHW Exemplar: Managing Hypertension in an Urban Community. *J Comm Pub Health Nurs .* 2016;2:135.
201. Pal N, Mandal S, Shiva K, Kumar B. Pharmacognostical, Phytochemical and Pharmacological Evaluation of *Mallotus philippensis*. *Journal of Drug Delivery and Therapeutics.* 2022 Sep 20;12(5):175-81.
202. Singh A, Mandal S. Ajwain (*Trachyspermum ammi* Linn): A review on Tremendous Herbal Plant with Various Pharmacological Activity. *International Journal of Recent Advances in Multidisciplinary Topics.* 2021 Jun 9;2(6):36-8.
203. Mandal S, Jaiswal V, Sagar MK, Kumar S. Formulation and evaluation of carica papaya nanoemulsion for treatment of dengue and thrombocytopenia. *Plant Arch.* 2021;21:1345-54.
204. Mandal S, Shiva K, Kumar KP, Goel S, Patel RK, Sharma S, Chaudhary R, Bhati A, Pal N, Dixit AK. Ocular drug delivery system (ODDS): Exploration the challenges and approaches to improve ODDS. *Journal of Pharmaceutical and Biological Sciences.* 2021 Jul 1;9(2):88-94.
205. Ali SA, Pathak D, Mandal S. A REVIEW OF CURRENT KNOWLEDGE ON AIRBORNE TRANSMISSION OF COVID-19 AND THEIR RELATIONSHIP WITH ENVIRONMENT. *International Journal of Pharma Professional's Research (IJPPR).* 2023;14(1):1-5.
206. Shiva K, Mandal S, Kumar S. Formulation and evaluation of topical antifungal gel of fluconazole using aloe vera gel. *Int J Sci Res Develop.* 2021;1:187-93.
207. Vishvakarma P, Mandal S, Verma A. A REVIEW ON CURRENT ASPECTS OF NUTRACEUTICALS AND DIETARY SUPPLEMENTS. *International Journal of Pharma Professional's Research (IJPPR).* 2023;14(1):78-91.
208. Ali S, Farooqui NA, Ahmad S, Salman M, Mandal S. CATHARANTHUS ROSEUS (SADABAHAR): A BRIEF STUDY ON MEDICINAL PLANT HAVING DIFFERENT PHARMACOLOGICAL ACTIVITIES. *Plant Archives.* 2021;21(2):556-9.
209. MANDAL S, JAISWAL DV, SHIVA K. A review on marketed Carica papaya leaf extract (CPLE) supplements for the treatment of dengue fever with thrombocytopenia and its drawback. *International Journal of Pharmaceutical Research.* 2020 Jul;12(3).
210. Mandal S, Vishvakarma P, Verma M, Alam MS, Agrawal A, Mishra A. *Solanum Nigrum* Linn: An Analysis Of The Medicinal Properties Of The Plant. *Journal of Pharmaceutical Negative Results.* 2023 Jan 1:1595-600.

*IJPPR (2023), Vol. 14, Issue 2*

211. Vishvakarma P, Mandal S, Pandey J, Bhatt AK, Banerjee VB, Gupta JK. An Analysis Of The Most Recent Trends In Flavoring Herbal Medicines In Today's Market. *Journal of Pharmaceutical Negative Results*. 2022 Dec 31:9189-98.

212. Mandal S, Pathak D, Rajput K, Khan S, Shiva K. THROMBOPHOB-INDUCED ACUTE URTICARIA: A CASE REPORT AND DISCUSSION OF THE CASE. *International Journal of Pharma Professional's Research (IJPPR)*. 2022;13(4):1-4.

213. Mandal S, Shiva K, Yadav R, Sen J, Kori R. LEIOMYOSARCOMA: A CASE REPORT ON THE PREOPERATIVE DIAGNOSTIC CRITERIA. *International Journal of Pharma Professional's Research (IJPPR)*. 2022;13(4):1-4.

214. Mandal S, Vishvakarma P, Mandal S. Future Aspects And Applications Of Nanoemulgel Formulation For Topical Lipophilic Drug Delivery. *European Journal of Molecular & Clinical Medicine*.;10(01):2023.

215. Chawla A, Mandal S, Vishvakarma P, Nile NP, Lokhande VN, Kakad VK, Chawla A. Ultra-Performance Liquid Chromatography (Uplc).